

Regional bulletin for the availability of antimalarial medicines: Fourth Quarter 2014

Volume 4 Number 1
2014



Plataforma Regional sobre
Acceso e Innovación para
Tecnologías Sanitarias

PRAIS

www.paho.org/prais

This bulletin is developed through a collaborative effort between the National Malaria Control Programs of the Region of the Americas, PAHO/WHO and SIAPS/USAID to facilitate sharing of information between countries in the Americas. The objectives of the bulletin are to increase awareness of stocks of antimalarial medicine, generate stock out alerts and promote exchanges and donations of antimalarial medicines between countries.

This bulletin is based on information provided by countries in South and Central America who participate in the Amazon Malaria Initiative (AMI) and are members of the Amazon Network for the Surveillance of Antimalarial Drug Resistance (RAVREDA). The bulletin offers information on the availability of medicines in central and regional medical stores that allow countries' decision makers to assure uninterrupted supply.

The following tables detail the availability of antimalarial medicines for each country. Stock out is considered zero availability in the storerooms.

The indicator of months of availability is calculated by each country by dividing the availability of medicines by the average monthly consumption or distribution. The average consumption is found by dividing the distribution or consumption over the previous year by 12.

This fourth bulletin includes information from ten countries, five from South America and five from Central America. Seven countries sent central and regional level data.



Availability of medicines for the fourth quarter, 2014

Medications			BELIZE					BRAZIL				
			Central			Department		Central			Department	
			Obligatory medication based on the Standard Treatment Guidelines (1=yes ; 0=no)	Units of medications available	Months of availability according to distribution/ consumption	Units of medications available	Months of availability according to distribution/ consumption	Obligatory medication based on the Standard Treatment Guidelines (1=yes ; 0=no)	Units of medications available	Months of availability according to distribution/ consumption	Units of medications available	Months of availability according to distribution/ consumption
P. falciparum treatments	001	Artemether-Lumefantrine 20/120 mg X 6 tablet						1	22,590	14.50		
	002	Artemether-Lumefantrine 20/120 mg X 12 tablet						1	28,830	13.97		
	003	Artemether-Lumefantrine 20/120 mg X 18 tablet						1	26,520	12.12		
	004	Artemether-Lumefantrine 20/120 mg X 24 tablet	1	5.00	0.00	0.00	0.00	1	20,370	4.79		
	005	Artesunate 50 mg tablet										
	006	Artesunate 100 mg tablet										
	007	Artesunate 250 mg tablet										
	008	Artesunate+ SP (Children)										
	009	Artesunate+ SP (Adolescent)										
	010	Artesunate+ SP (Adults)										
	011	Artesunate-Mefloquine 25/55 mg x 3 tablet.						1	290	0.21		
	012	Artesunate-Mefloquine 25/55 mg x 6 tablet.						1	300	0.23		
	013	Artesunate-Mefloquine 100/220 mg x 3 tablet.						1	270	0.19		
	014	Artesunate+Mefloquine 100/220 mg x 6 tablet.						1	40	0.03		
	015	Mefloquine 250 mg tablet	0	500	10.00	0	0.00					
	016	Sulfadoxine-Pyrimethamine 25/500mg tablet										
P. vivax treatments	017	Chloroquine phosphate 150 mg tablet	1	71,290	14.26	8,800	2.20	1	2,413,000	10.53		
	018	Chloroquine phosphate 100 mg tablet	0	12,000	0.00	0	0.00					
	019	Primaquine phosphate 5 mg tablet	1	0	0.00	0	0.00	1	450,500	5.52		
	020	Primaquine phosphate 7.5 mg tablet										
	021	Primaquine phosphate 15 mg tablet	1	12,000	333.33	1,901	27.16	1	1,651,000	10.28		
Severe and Special Case malaria treatments	022	Artemether 80 mg/1 ml, 1 ml ampoules						1	18,505	17.57		
	023	Artesunate rectal 50 mg										
	024	Artesunate rectal 100 mg										
	025	Artesunate sodium bicarbonate 60 mg/1 ml ampoule						1	27,771	10.53		
	026	Clindamycin Hydrochloride 300 mg Capsule						1	0	0.00		
	027	Clindamycin Phosphate 150 mg/ mL x 4 mL injectable						1	0	0.00		
	028	Clindamycin Hydrochloride 150 mg Capsule										
	029	Clindamycin 75mg/5mL suspension										
	030	Doxycycline 100 mg Capsule						1	10,065	12.14		
	031	Quinine Hydrochloride 300 mg/ mL x 2 mL injectable	0	100		0.00	0.00	1	59,200	23.06		
	032	Quinine Hydrochloride 600 mg/ mL x 2 mL injectable										
033	Quinine Dihydrochloride 125 mg/ mL x 4 mL injectable											
034	Quinine Dihydrochloride 300 mg/ mL x 2 mL injectable											
035	Quinine Dihydrochloride 600mg/ml x 2 mL injectable											
036	Quinine Sulfate 300mg tablet	0	200		0.00	0.00						
037	Quinine Sulfate 500 mg tablet						1	60,500	9.81			

Source: Consolidated National Report from Countries

Availability of medicines for the fourth quarter, 2014

Medications			COLOMBIA				ECUADOR						
			Central			Department		Central			Department		
			Obligatory medication based on the Standard Treatment Guidelines (1=yes ; 0=no)	Units of medications available	Months of availability according to distribution/ consumption	Units of medications available	Months of availability according to distribution/ consumption	Obligatory medication based on the Standard Treatment Guidelines (1=yes ; 0=no)	Units of medications available	Months of availability according to distribution/ consumption	Units of medications available	Months of availability according to distribution/ consumption	
P. falciparum treatments	001	Artemether-Lumefantrine 20/120 mg X 6 tablet	1	570	6.33	172	1.93	1	60	44.72	1,561	1,163.48	
	002	Artemether-Lumefantrine 20/120 mg X 12 tablet	1	2,782	12.65	722	2.34	1	492	366.71	4,321	3,220.62	
	003	Artemether-Lumefantrine 20/120 mg X 18 tablet	1	1,715	4.25	639	1.50	1	108	80.50	4,807	3,582.86	
	004	Artemether-Lumefantrine 20/120 mg X 24 tablet	1	15,416	7.56	4,711	2.32	1	0	0.00	9,409	701.29	
	005	Artesunate 50 mg tablet											
	006	Artesunate 100 mg tablet											
	007	Artesunate 250 mg tablet											
	008	Artesunate+ SP (Children)											
	009	Artesunate+ SP (Adolescent)											
	010	Artesunate+ SP (Adults)											
	011	Artesunate-Mefloquine 25/55 mg x 3 tablet.											
	012	Artesunate-Mefloquine 25/55 mg x 6 tablet.											
	013	Artesunate-Mefloquine 100/220 mg x 3 tablet.											
	014	Artesunate+Mefloquine 100/220 mg x 6 tablet.											
	015	Mefloquine 250 mg tablet											
	016	Sulfadoxine-Pyrimethamine 25/500mg tablet											
P. vivax treatments	017	Chloroquine phosphate 150 mg tablet	1	889,530	13.36	210,683	3.55	1	22,237	122.97	10,310	57.01	
	018	Chloroquine phosphate 100 mg tablet											
	019	Primaquine phosphate 5 mg tablet	1	199,195	10.8	231,162	14.83						
	020	Primaquine phosphate 7.5 mg tablet						1	0	0.00	2,676	105.70	
	021	Primaquine phosphate 15 mg tablet	1	12,590	0.23	62,638	0.81	1	588	2.32	17,726	70.02	
Severe and Special Case malaria treatments	022	Artemether 80 mg/1 ml, 1 ml ampoules											
	023	Artesunate rectal 50 mg	1	2,322	7.26	2,112	4.06						
	024	Artesunate rectal 100 mg											
	025	Artesunate sodium bicarbonate 60 mg/1 ml ampoule	1	254	1.33	1,334	2.85	1	5	0.37	155	11.55	
	026	Clindamycin Hydrochloride 300 mg Capsule						1	674	50.24	519	38.68	
	027	Clindamycin Phosphate 150 mg/ mL x 4 mL injectable											
	028	Clindamycin Hydrochloride 150 mg Capsule											
	029	Clindamycin 75mg/5mL suspension											
	030	Doxycycline 100 mg Capsule											
	031	Quinine Hydrochloride 300 mg/ mL x 2 mL injectable	1	1,202	120.20	1,834	1.93						
	032	Quinine Hydrochloride 600 mg/ mL x 2 mL injectable											
033	Quinine Dihydrochloride 125 mg/ mL x 4 mL injectable												
034	Quinine Dihydrochloride 300 mg/ mL x 2 mL injectable												
035	Quinine Dihydrochloride 600mg/ml x 2 mL injectable												
036	Quinine Sulfate 300mg tablet	1	55,920	140.86	13,129	7.81	1	106	1.88	740	13.13		
037	Quinine Sulfate 500 mg tablet												

Source: Consolidated National Report from Countries

Availability of medicines for the fourth quarter, 2014

Medications			GUATEMALA					GUYANA				
			Central			Department		Central			Department	
			Obligatory medication based on the Standard Treatment Guidelines (1=yes ; 0=no)	Units of medications available	Months of availability according to distribution/ consumption	Units of medications available	Months of availability according to distribution/ consumption	Obligatory medication based on the Standard Treatment Guidelines (1=yes ; 0=no)	Units of medications available	Months of availability according to distribution/ consumption	Units of medications available	Months of availability according to distribution/ consumption
P. falciparum treatments	001	Artemether-Lumefantrine 20/120 mg X 6 tablet						1	58,500	650.00		
	002	Artemether-Lumefantrine 20/120 mg X 12 tablet						1	77,376	429.87		
	003	Artemether-Lumefantrine 20/120 mg X 18 tablet						1	240,156	71.48		
	004	Artemether-Lumefantrine 20/120 mg X 24 tablet						1	0	0.00		
	005	Artesunate 50 mg tablet										
	006	Artesunate 100 mg tablet										
	007	Artesunate 250 mg tablet										
	008	Artesunate+ SP (Children)										
	009	Artesunate+ SP (Adolescent)										
	010	Artesunate+ SP (Adults)										
	011	Artesunate-Mefloquine 25/55 mg x 3 tablet.										
	012	Artesunate-Mefloquine 25/55 mg x 6 tablet.										
	013	Artesunate-Mefloquine 100/220 mg x 3 tablet.										
	014	Artesunate+Mefloquine 100/220 mg x 6 tablet.										
	015	Mefloquine 250 mg tablet						1.00	10,300.00	0.00		
	016	Sulfadoxine-Pyrimethamine 25/500mg tablet										
P. vivax treatments	017	Chloroquine phosphate 150 mg tablet	1	0	0.00	48,410	4.03	1	350,000	74.99		
	018	Chloroquine phosphate 100 mg tablet										
	019	Primaquine phosphate 5 mg tablet	1	5,116	4.6	106,889	4.82					
	020	Primaquine phosphate 7.5 mg tablet						1	50,000	5.36		
	021	Primaquine phosphate 15 mg tablet	1	0	0.00	24,486	2.23	1	810,000	21.69		
Severe and Special Case malaria treatments	022	Artemether 80 mg/1 ml, 1 ml ampoules						1	0	0.00		
	023	Artesunate rectal 50 mg										
	024	Artesunate rectal 100 mg										
	025	Artesunate sodium bicarbonate 60 mg/1 ml ampoule										
	026	Clindamycin Hydrochloride 300 mg Capsule						1	0	0.00		
	027	Clindamycin Phosphate 150 mg/ mL x 4 mL injectable						1	0	0.00		
	028	Clindamycin Hydrochloride 150 mg Capsule										
	029	Clindamycin 75mg/5mL suspension										
	030	Doxycycline 100 mg Capsule										
	031	Quinine Hydrochloride 300 mg/ mL x 2 mL injectable										
	032	Quinine Hydrochloride 600 mg/ mL x 2 mL injectable										
	033	Quinine Dihydrochloride 125 mg/ mL x 4 mL injectable										
	034	Quinine Dihydrochloride 300 mg/ mL x 2 mL injectable										
	035	Quinine Dihydrochloride 600mg/ml x 2 mL injectable						1	1,702	30.95		
	036	Quinine Sulfate 300mg tablet										
	037	Quinine Sulfate 500 mg tablet										

Source: Consolidated National Report from Countries

Availability of medicines for the fourth quarter, 2014

Medications			HONDURAS					NICARAGUA					
			Central			Department		Central			Department		
			Obligatory medication based on the Standard Treatment Guidelines (1=yes ; 0=no)	Units of medications available	Months of availability according to distribution/consumption	Units of medications available	Months of availability according to distribution/consumption	Obligatory medication based on the Standard Treatment Guidelines (1=yes ; 0=no)	Units of medications available	Months of availability according to distribution/consumption	Units of medications available	Months of availability according to distribution/consumption	
P. falciparum treatments	001	Artemether-Lumefantrine 20/120 mg X 6 tablet											
	002	Artemether-Lumefantrine 20/120 mg X 12 tablet											
	003	Artemether-Lumefantrine 20/120 mg X 18 tablet											
	004	Artemether-Lumefantrine 20/120 mg X 24 tablet											
	005	Artesunate 50 mg tablet											
	006	Artesunate 100 mg tablet											
	007	Artesunate 250 mg tablet											
	008	Artesunate+ SP (Children)											
	009	Artesunate+ SP (Adolescent)											
	010	Artesunate+ SP (Adults)											
	011	Artesunate-Mefloquine 25/55 mg x 3 tablet.											
	012	Artesunate-Mefloquine 25/55 mg x 6 tablet.											
	013	Artesunate-Mefloquine 100/220 mg x 3 tablet.											
	014	Artesunate+Mefloquine 100/220 mg x 6 tablet.											
	015	Mefloquine 250 mg tablet											
	016	Sulfadoxine-Pyrimethamine 25/500mg tablet	1	0	0.00								
P. vivax treatments	017	Chloroquine phosphate 150 mg tablet	1	528,500	7.72			1	758,920	3.36	997,191	4.42	
	018	Chloroquine phosphate 100 mg tablet											
	019	Primaquine phosphate 5 mg tablet	1	240,230	9.93			1	444,117	3.54	373,054	2.98	
	020	Primaquine phosphate 7.5 mg tablet											
	021	Primaquine phosphate 15 mg tablet	1	369,620	7.14			1	88,841	0.78	448,512	3.92	
Severe and Special Case malaria treatments	022	Artemether 80 mg/1 ml, 1 ml ampoules											
	023	Artesunate rectal 50 mg											
	024	Artesunate rectal 100 mg											
	025	Artesunate sodium bicarbonate 60 mg/1 ml ampoule											
	026	Clindamycin Hydrochloride 300 mg Capsule						1	1,026,930	8.24	220,805	1.77	
	027	Clindamycin Phosphate 150 mg/ mL x 4 mL injectable											
	028	Clindamycin Hydrochloride 150 mg Capsule											
	029	Clindamycin 75mg/5mL suspension											
	030	Doxycycline 100 mg Capsule											
	031	Quinine Hydrochloride 300 mg/ mL x 2 mL injectable						1	929	6.68	1,461	10.44	
	032	Quinine Hydrochloride 600 mg/ mL x 2 mL injectable											
	033	Quinine Dihydrochloride 125 mg/ mL x 4 mL injectable											
034	Quinine Dihydrochloride 300 mg/ mL x 2 mL injectable	1	41	4.10									
035	Quinine Dihydrochloride 600mg/ml x 2 mL injectable												
036	Quinine Sulfate 300mg tablet	1	0	0.00									
037	Quinine Sulfate 500 mg tablet												

Source: Consolidated National Report from Countries

Availability of medicines for the fourth quarter, 2014

Medications			PANAMA				PERU					
			Central			Department		Central			Department	
			Obligatory medication based on the Standard Treatment Guidelines (1=yes ; 0=no)	Units of medications available	Months of availability according to distribution/ consumption	Units of medications available	Months of availability according to distribution/ consumption	Obligatory medication based on the Standard Treatment Guidelines (1=yes ; 0=no)	Units of medications available	Months of availability according to distribution/ consumption	Units of medications available	Months of availability according to distribution/ consumption
P. falciparum treatments	001	Artemether-Lumefantrine 20/120 mg X 6 tablet	1	0	0.00	0	0.00					
	002	Artemether-Lumefantrine 20/120 mg X 12 tablet	1	0	0.00	0	0.00					
	003	Artemether-Lumefantrine 20/120 mg X 18 tablet	1	0	0.00	0	0.00					
	004	Artemether-Lumefantrine 20/120 mg X 24 tablet	1	120	5.00	0	0.00					
	005	Artesunate 50 mg tablet						1	149,988.00	451.77	25,097	38.26
	006	Artesunate 100 mg tablet										
	007	Artesunate 250 mg tablet						1	6,818	6.87	15,038	7.66
	008	Artesunate+ SP (Children)										
	009	Artesunate+ SP (Adolescent)										
	010	Artesunate+ SP (Adults)										
	011	Artesunate-Mefloquine 25/55 mg x 3 tablet.										
	012	Artesunate-Mefloquine 25/55 mg x 6 tablet.										
	013	Artesunate-Mefloquine 100/220 mg x 3 tablet.										
	014	Artesunate+Mefloquine 100/220 mg x 6 tablet.										
	015	Mefloquine 250 mg tablet						1	100,070	50.41	1,279	0.33
	016	Sulfadoxine-Pyrimethamine 25/500mg tablet	0	9,000								
P. vivax treatments	017	Chloroquine phosphate 150 mg tablet	1	12,000	0.21	34,510	16.01	1	297,180	12.89	713,462	21.08
	018	Chloroquine phosphate 100 mg tablet										
	019	Primaquine phosphate 5 mg tablet	1	15,000	3.00	0	0.00					
	020	Primaquine phosphate 7.5 mg tablet						1	0	0.00	0	0.00
	021	Primaquine phosphate 15 mg tablet	1	369,000	12.72	52,620	15.03	1	213,290	6.61	199,677	4.21
Severe and Special Case malaria treatments	022	Artemether 80 mg/1 ml, 1 ml ampoules										
	023	Artesunate rectal 50 mg										
	024	Artesunate rectal 100 mg										
	025	Artesunate sodium bicarbonate 60 mg/1 ml ampoule						0	238		26	
	026	Clindamycin Hydrochloride 300 mg Capsule						0	0		729,152	
	027	Clindamycin Phosphate 150 mg/ mL x 4 mL injectable						0	0		10,023	
	028	Clindamycin Hydrochloride 150 mg Capsule										
	029	Clindamycin 75mg/5mL suspension										
	030	Doxycycline 100 mg Capsule						0	0		1,083,385	
	031	Quinine Hydrochloride 300 mg/ mL x 2 mL injectable						0			3,975	
	032	Quinine Hydrochloride 600 mg/ mL x 2 mL injectable										
	033	Quinine Dihydrochloride 125 mg/ mL x 4 mL injectable										
	034	Quinine Dihydrochloride 300 mg/ mL x 2 mL injectable						1	4,426	80.47	0	0.00
	035	Quinine Dihydrochloride 600mg/ml x 2 mL injectable										
	036	Quinine Sulfate 300mg tablet						1	0	0.00	207	0.56
	037	Quinine Sulfate 500 mg tablet										

Source: Consolidated National Report from Countries

Indicators reported for the fourth quarter, 2014

INDICATORS	Belize		Brasil		Colombia		Ecuador		Guatemala		Guyana		Honduras		Nicaragua		Panama		Peru	
	Central	Depart	Central	Depart	Central	Depart	Central	Depart	Central	Depart	Central	Depart	Central	Depart	Central	Depart	Central	Depart	Central	Depart
No. of department warehouses that report medication availability data.		7				34		9		22						19		14		33
% of regional stores that report stockout in one or more antimalarials required by the Standard Treatment Guidelines (STG).		100%				53%		73%		59%						5%		7%		93%
Number of medicines required in the Standard Treatment Guidelines (STG)	4	4	18		11	11	10	10	3	3	12		6		5	5	7	7	8	8
Number of STG medicines that are available.	3	2	16		11	11	8	10	1	3	8		4		5	5	4	2	6	6
% of STG medications available	75%	50%	89%		100%	100%	80%	100%	33%	100%	67%		67%		100%	100%	57%	29%	75%	75%
% of STG medications not available	25%	50%	11%		0%	0%	20%	0%	67%	0%	33%		33%		0%	0%	43%	71%	25%	25%
% of STG medications with availability less than the minimum security stock (3 months)	50%	75%	33%		18%	64%	50%	0%	67%	33%	42%		33%		20%	40%	57%	71%	25%	50%
% of STG medications which are overstocked (more than 24 months of availability)	25%	25%	0%		18%	0%	50%	80%	0%	0%	42%		0%		0%	0%	0%	0%	38%	13%

This bulletin was elaborated within the framework of AMI/RAVREDA with assistance from PAHO/WHO, specifically the Medicines and Health Technologies (HSS/MT) unit and the Regional Malaria Program (CHA/VT) and the USAID funded program Systems for Improved Access to Pharmaceuticals and Services (SIAPS). Data for the report was sent by the National Malaria Control Programs of the participating countries. The consolidation and editing of the bulletin was completed by the regional team of the PAHO/WHO Strategic Fund, which utilized the previous format developed by DIGEMID and SIAPS/USAID as a reference

